DMAKO-20 as a new multitarget anticancer prodrug activated by the tumor specific CYP1B1 enzyme - Cui, J; Zhang, X; Huang, G; Zhang, Q; Dong, J; Sun, G; Meng, Q; Li, S (Mol Pharm, 2019)